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Background
Type-A botulinum toxin (BoNTA) therapy has emerged
as an effective treatment for chronic headache (CH) [1].
No conclusive data exists about BoNTA efficacy in CH
comorbid with anxiety and depression disorders. Our
open prospective study aimed to evaluate CH BoNTA
treatment efficacy regarding clinical and psychopatholo-
gical variables in a multidisciplinary setting.
Materials and methods
We treated 32 CH patients (8 males; 24 females; 44.76
±11.23 mean age) with 190-units BoNTA injections.
Sessions took place from January 2014 to June 2015
once every 3 months; patients received headache educa-
tion; at the baseline (T0) and at the final follow-up (T1)
patients completed a headache diary, pain Numerical
Rating Scale (NRS), Migraine Disability Assessment
(MIDAS), Zung Self-Rating Anxiety Scale (SAS) and
Zung Self-Rating Depression Scale (SDS). We consid-
ered patients responders if they had > 50% reduction in
headache frequency and/or pain intensity compared
with baseline. Using SOFA Statistics 1.4.4 software, we
calculated descriptive indicators and evaluated treatment
effect using paired-samples Student’s t-test on clinical
and psychosocial variables between T0 and T1. We set
p < 0.05 as threshold of statistical significance.
Results
At T0 headache frequency (M±DS) was 23.71±5.38 head-
ache days/month; NRS score was 9.10±0.94; MIDAS score
was 57.59±24.72; SAS score was 48.38±12.16; SDS score
was 46.68±14.31. At T1 headache frequency (M±DS) was
9.14±8.31 headache days/month; NRS score was 6.33
±2.33; MIDAS score was 21.517±20.19; SAS score was
39.38±9.19; SDS score was 36.01±10.32. Twenty-one
patients (65.25%) showed psychopathological comorbid-
ity. We observed response to treatment in 23 patients
(71.87%) with a statistically significant treatment effect
on headache frequency (t = 8.539; p < 0.001), pain
intensity (t = 5.451; p < 0.001), disability (t = 5.701; p <
0.001), anxiety (t = 3.457; p < 0.005) and depression (t =
2.59; p < 0.05).
Conclusions
Our data support that BoNTA in a multidisciplinary set-
ting is an effective treatment for chronic headache,
potentially addressing pain-related affective disorders.
Further developments of our study could evaluate the
effectiveness of enhanced psychological interventions,
such as stress management, as a complement to the
biomedical treatment.
Written informed consent to publish was obtained from
the patient(s).
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